Esophageal adenocarcinoma is now the fastest growing cancer category in western men. Additionally, the prognosis of locally advanced disease has remained static despite current management advances. These facts clearly indicate the necessity of developing novel therapeutic approaches for esophageal adenocarcinoma. Even though conditionally replicative adenoviruses (CRAds) offer a novel and potent modality to approach solid tumors of the gastrointestinal tract, esophageal adenocarcinoma cells are extremely resistant to adenoviral infection due to minimal expression of the adenoviral primary receptor (coxsackie-adenovirus receptor, CAR). Furthermore, the lack of promoters with selectivity for esophageal adenocarcinoma has hindered the construction of CRAds that can selectively replicate in target tumor cells to achieve a useful therapeutic index for clinical utility. Lastly, absence of a non-invasive in vivo imaging method to detect CRAd replication and spread has hampered an understanding of CRAd biology in vivo. To achieve full therapeutic potential of CRAds for esophageal adenocarcinoma, we propose the construction of promoter-driven, infectivity-enhanced CRAds with imaging capabilities. To address the first issue, we have identified three promising promoters that exhibit favorable """"""""tumor versus liver"""""""" and """"""""tumor versus normal mucosa"""""""" differentials which are critical for utility in an adenoviral context. As well, we have developed methods to alter the tropism of adenoviruses, thereby achieving infectivity enhancement of tumor target ceils. The incorporation of an RGD4C motif in the HI loop of the fiber-knob region and Ad5/3 chimeric fiber modification has been shown to dramatically improve the infectious potency of adenovirus on esophageal adenocarcinoma cells. These findings offer solutions to the problem of esophageal adenocarcinoma cell resistance to adenoviral infection. In addition, we will configure optical and radiological imaging functions into our infectivity enhanced CRAds driven by optimal promoter. These features provide minimally invasive detection of CRAd replication and spread in a clinical setting, serving as a monitoring system with relevance to patient safety. Thus, it is obvious that infectivity-enhanced CRAds controlled by an optimal promoter element and possessing an imaging capability will be a therapeutic agent with great clinical utility for esophageal adenocarcinoma. The applicability of these modalities will be established from both toxicological and tumoricidal effect standpoints along with confirmation of CRAd functionality by optical and radiological imaging.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK063615-04
Application #
7072246
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Hamilton, Frank A
Project Start
2003-08-01
Project End
2006-10-31
Budget Start
2006-06-01
Budget End
2006-10-31
Support Year
4
Fiscal Year
2006
Total Cost
$58,738
Indirect Cost
Name
University of Alabama Birmingham
Department
Surgery
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kosaka, Takashi; Davydova, Julia; Ono, Hidetaka A et al. (2015) Imaging and Antitumoral Effect of a Cyclo-oxygenase 2-specific Replicative Adenovirus for Small Metastatic Gastric Cancer Lesions. Anticancer Res 35:5201-10
Yamasaki, Satoshi; Miura, Yoshiaki; Davydova, Julia et al. (2013) A single intraduodenal administration of human adenovirus 40 vaccine effectively prevents anaphylactic shock. Clin Vaccine Immunol 20:1508-16
Yamamoto, Masato; Curiel, David T (2010) Current issues and future directions of oncolytic adenoviruses. Mol Ther 18:243-50
Davydova, Julia; Gavrikova, Tatyana; Brown, Eric J et al. (2010) In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci 101:474-81
Yamasaki, Satoshi; Miura, Yoshiaki; Brown, Eric et al. (2010) Development of a method for effective amplification of human adenovirus 40. Arch Virol 155:1059-68
Arrington, Amanda K; Dahlberg, Peter S; Davydova, Julia et al. (2009) ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. Surgery 146:213-9
Nelson, Amy R; Davydova, Julia; Curiel, David T et al. (2009) Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 100:2181-7
Arrington, Amanda K; Davydova, Julia; Vickers, Selwyn M et al. (2009) Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas. J Gastrointest Surg 13:1754-61
Ramirez, Pedro J; Vickers, Selwyn M; Ono, Hidetaka A et al. (2008) Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg 195:481-90
Le, Long P; Le, Helen N; Nelson, Amy R et al. (2006) Core labeling of adenovirus with EGFP. Virology 351:291-302

Showing the most recent 10 out of 25 publications